Question Bank › Conviction backed by things in hand

Conviction backed by things in hand

Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond

Calls Tested
396
Answered YES
29
Hit Rate
7.3%
rare by design

CTO Realty Growth, Inc. (CTO) — this company's answers

NO on the Q2 2023 call 2023-07-28 B
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否明确表达了对业务在未来几个季度将显著提升的信心,并且这种信心是否基于公司已经掌握或正在发生的具体事实,而非市场条件或一般乐观情绪。 分析: - 管理层在电话中提到了多项具体进展:收购了多个物业(Plaza at Rockwall、Exchange at Gwinnett等),租赁活动强劲(签署了24份租约,可比租金增长25%),并提到了具体物业的租赁进展(如Collection at Forsyth、West Broad Village)。这些是已经发生或正在进行的活动。 - 关于未来,管理层重申了2023年指引,并提到预计下半年有资产处置活动,但并未明确表示业务将“显著提升”到更高水平。他们提到租赁活动在最近60天有所增加,但整体语气是稳健推进,而非强调一个大的跃升。 - 管理层在回答问题时,提到了具体租户、物业和租赁情况,但并未明确说“我们预计业务将大幅增长”或类似表述。他们更多是在描述当前进展和未来计划,但缺乏一个明确的“我们正进入一个显著更高水平”的声明。 - 证据方面,他们确实有具体事实(已签署的租约、已收购的物业),但关于“未来几个季度业务将显著提升”的明确信心表述并不突出。他们提到租赁活动强劲,但并未将其与一个明确的“步进式提升”联系起来。 因此,虽然管理层提供了具体事实,但并未明确表达“业务将显著提升”的坚定信念。他们更多是在描述当前运营和未来计划,而非强调一个大的跃升。所以答案应为NO。

← Back to the full CTO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that conviction in CONCRETE THINGS THE COMPANY ALREADY HAS IN HAND OR ALREADY HAPPENING — rather than in market conditions, industry recovery, or general optimism? Answer YES when BOTH halves come through together in management's own words, as one coherent posture, in whatever form fits the business: (1) STATED CONVICTION ABOUT A STEP-UP AHEAD. Management plainly conveys that it expects the business to be meaningfully bigger, busier, or stronger over roughly the coming year — not merely steady continuation, and not vague aspiration. The conviction should be unmistakable in how management talks about where the company is headed: confident, specific in direction, and owned by management itself. (2) THE CONVICTION RESTS ON EVIDENCE ALREADY IN THE COMPANY'S POSSESSION. When management explains WHY it is confident, it points to real, present-tense substance — in whatever form fits the industry — such as: business already won, signed, booked, or committed that has not yet fully shown up in results; work, orders, customers, or volumes already arriving or ramping now; a capability, capacity, product, or asset already built or in place that the growth will run through; observable customer behavior already occurring; or progress already made that management can describe concretely. The evidence should be specific enough that management is describing things that exist and can be pointed to, not projections, pipeline hopes, or a market thesis. Where analysts probe or doubt, management responds with this kind of already-real substance rather than with reassurance alone. Answer NO if management's confidence rests mainly on expected market recovery, industry tailwinds, macro improvement, pricing environments, seasonal patterns, or customer sentiment that has not yet converted into anything the company holds. NO if the forward talk is generic optimism, mission language, or big-market framing without concrete present-tense support. NO if the call conveys steady continuation, a defense of weak results, or a turnaround still promised rather than evidenced. NO if the evidence offered is only a raised financial guidance number, an analyst's model, or third-party forecasts. NO if the conviction and the evidence never connect — strong facts reported but no stated step-up ahead, or a stated step-up with nothing in hand behind it. NO if the posture appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
ZVIA Zevia PBC Q1 2022 2022-05-12 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
CMTL Comtech Telecommunications Corp. Q1 2019 2018-12-07 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
INSM Insmed Incorporated Q4 2017 2018-02-23 B
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
FLEX Flex Ltd. Q1 2018 2017-07-28 F
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
ANIP ANI Pharmaceuticals, Inc. Q4 2016 2017-03-02 B+
GPOR Gulfport Energy Corporation Q4 2016 2017-02-14 A
WYY WidePoint Corporation Q3 2016 2016-11-09 D
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.

More from the question bank

Room to raise the ceilingSelling the shovels to a customer who just gStaircase quarter: best recent period just rCommitment step-up grounded in demand alreadCheap-to-serve incremental businessTheir own money is on the lineAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.